To recover your password please fill in your email address
Please fill in below form to create an account with us
Long term study of LDL-c Lowering with Evolocumab: Observational Follow-up after the FOURIER OUTCOMES study (Protocol number: CTC 0173). Long-term post-trial (legacy) beneficial effects have been reported with statins, niacin, hypoglycaemic therapy and fibrates. Whether similar effects are seen after LDL-cholesterol (LDL-c) lowering by PCSK9 inhibition is currently unknown. This study aims to evaluate potential long-term effects of evolocumab treatment in patients who completed the FOURIER OUTCOMES trials, on cardiovascular outcomes.
|
Trial Summary: |
Participants will be remotely assessed (via questionnaire) upon entry into FOURIER LEGACY, approximately 6 and 12 months later and then approximately annually to obtain a total of 5 years’ follow-up after the date of last contact in FOURIER OUTCOMES to collect details of cardiovascular hospitalisations, mortality and lipid lowering therapy classes. |
|
Supported By: |
University of Sydney; coordinated by NHMRC CTC |
|
Eligibility: |
Participants in selected countries who completed the FOURIER OUTCOMES clinical trial. |
|
Registration ID: |
NCT04128475 (CT.gov) and ACTRN12621001009808 (ANZCTR) |
|
Participation: |
Minimum of 10,000 globally. |
|
Australian Lead Group: |
NHMRC CTC |
|
Status: |
Close out |
|
Activation Date: |
5 Feb 2020 |
|
Chairs: |
Professor Tony Keech |
|
Contact: |